TLR4-Based Immunotherapeutics in Cancer: A Review of the Achievements and Shortcomings.
Sign Up to like & getrecommendations! Published in 2018 at "Molecular pharmaceutics"
DOI: 10.1021/acs.molpharmaceut.8b00691
Abstract: Toll-like Receptor 4 (TLR4) agonists have had a long journey in the field of cancer immunotherapy. Nevertheless, despite the remarkable number of the TLR4 ligands that have gone through various preclinical and clinical stages, only… read more here.
Keywords: achievements shortcomings; tlr4 agonists; review; cancer immunotherapy ... See more keywords